May 2016, Vol. 5, No. 4
Serving All on the Oncology Care TeamLetter to Our Readers
Over the past decade, we’ve experienced tremendous changes in the way we care for and treat patients with cancer. From research targets to available treatments; from management strategies to the very makeup of the multidisciplinary team. The publishers of Personalized Medicine in Oncology (PMO) recognize that to provide the best care to our patients, it takes a village. As a result, the oncology care team has evolved to include growing roles for physicians, nurses, pathologists, nurse and patient navigators, and, of course, the patient. To best support the efforts of those on the team, our publishers have multiple journals designed for members of the care team. Most recently, the publishers of PMO and the Journal of Oncology Navigation & Survivorship launched a patient magazine called CONQUER: the patient voice. This magazine was created in the hope of providing valuable information to patients, family, friends, and caregivers. We are delighted that CONQUER has celebrated its 1-year anniversary and hope it has proved valuable to your patients. We encourage you to pass the word along to your patients that this resource is available to them by visiting www.conquer-magazine.com. They can also complete the postcard on the cover and mail it to begin receiving future issues to their home address.
Within this issue of PMO, we feature an interview with the Editor in Chief of our sister publication, Journal of Oncology Navigation & Survivorship, Lillie D. Shockney, RN, BS, MAS, Johns Hopkins University, about the incorporation of the oncology nurse navigator into our cancer care teams.
We also feature an article from Drs Najjar and Kirkwood about the state of personalized medicine in melanoma as well as an insightful summary of research on perspectives of personalized medicine from Drs Miller, Garfield, and Woodman.
As always, we are proud to present The Last Word from Dr Edward Abrahams of the Personalized Medicine Coalition. In this installment, Dr Abrahams writes about Vice President Biden’s Moonshot initiative.
Thank you for your loyal readership. We value your participation; please contact us with your intriguing case studies, article ideas, and feedback at firstname.lastname@example.org.
Al B. Benson III, MD, FACP, FASCO
Coeditor in Chief
Personalized Medicine in Oncology
Please visit www.conquer-magazine.com today.
A higher score on a composite index of homologous recombination deficiency (HRD) correlated with improved progression-free survival (PFS) and overall survival (OS) in ovarian cancer treated with platinum-containing chemotherapy, results of a tissue-based validation study showed. An HRD score that met or exceeded the predefined threshold reduced the hazard ratio [ Read More ]
The ability to analyze multiple genes at the same time has led to the estimate that 20% to 25% of women with ovarian cancer have an inherited mutation in a cancer-predisposing gene.1 Although this association has been noted for a while, until recently there were not enough data available to [ Read More ]